mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer

• US 8,257,924 B2
• Filed: 05/05/2011
• Issued: 09/04/2012
• Est. Priority Date: 12/24/2004
• Status: Active Grant

• Current Assignee: Stichting Katholieke Universiteit
• Original Assignee: Stichting Katholieke Universiteit
• Inventors: Hessels, Daphne, Verhaegh, Gerald, Schalken, Jack A., Witjes, Alfred J.
• Primary Examiner(s): Babic, Christopher M.
• Application Number:
  US13/101,440
• Publication Number:
  US 20120003640A1
• Time in Patent Office: 488 Days
• Field of Search: None
• US Class Current: 435/6.1
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2333/96455 Kallikrein (3.4.21.34; 3.4.21.35)
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and (b) correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.

Claims

1. A method for prognosing prostate cancer in a patient comprising:

a) obtaining a biological sample from said patient;

b) determining the amount of a prostate cancer specific PCA3 mRNA and the amount of a prostate-specific marker in said biological sample;

c) determining a ratio value of said amount of said prostate cancer specific PCA3 mRNA over said amount of prostate-specific marker; and

d) comparing said ratio value to at least one predetermined cut-off value;

wherein a ratio value above said predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below said predetermined cut-off value.

2. The method of claim 1, wherein said biological sample is:

urine, prostate tissue resection, prostate tissue biopsy, ejaculate or bladder washing.

3. The method of claim 2, wherein said biological sample is a urine sample obtained after a digital rectal examination.

4. The method of claim 1, wherein said amount of prostate-specific marker is the amount of prostate-specific marker mRNA.

9. The method of claim 1, wherein an amplification reaction is used for determining the amount of said prostate cancer specific PCA3 nucleic acid.

10. The method of claim 9, wherein said amplification reaction is:

a) polymerase chain reaction (PCR);

b) nucleic acid sequence-based amplification assay (NASBA);

c) transcription mediated amplification (TMA);

d) ligase chain reaction (LCR);

or

e) strand displacement amplification (SDA).

12. The method of claim 1, wherein the amount of said prostate cancer specific PCA3 mRNA is determined by using at least one oligonucleotide that hybridizes to a PCA3 nucleic acid sequence which is:

a) a nucleic acid sequence set forth in SEQ ID NO;

1;

b) a nucleic acid sequence set forth in SEQ ID NO;

2;

or

c) a nucleic acid sequence that hybridizes under high stringency conditions to a nucleic acid sequence in a) or b).

13. The method of claim 1, wherein the amount of prostate-specific marker protein contained in said biological sample is determined.

14. The method of claim 13, wherein an antibody is used to determine said amount of prostate-specific marker protein.

16. The method of claim 1, further comprising determining the Gleason score of a prostate sample from said patient and correlating said PCA3/prostate-specific marker ratio value and said Gleason score with a mortality risk associated with said prostate cancer.

17. The method of claim 16, wherein said PCA3/prostate-specific marker ratio value and said Gleason score is correlated with a prediction of drug efficacy, patient outcome and/or a forecast of prostate cancer risk.

21. The method of claim 1, wherein said prostate-specific marker is:

HK2/KLK2, PSMA, transglutaminase 4, acid phosphatase, PCGEM1, NKX3.1, prostate stem cell antigen (PSCA), prostate tumor inducing gene-1 (PTI-1), PDEF, TMPRSS2 or Prostase.

22. The method of claim 2, wherein said biological sample is from a urine sample collected not following a digital rectal examination.

5. A method for prognosing prostate cancer in a patient comprising:

a) contacting a biological sample from said patient with at least one oligonucleotide that hybridizes to a prostate cancer specific PCA3 mRNA;

b) contacting said biological sample with at least one oligonucleotide that hybridizes to a prostate-specific marker mRNA;

c) determining the amount of PCA3 mRNA and the amount of prostate-specific marker mRNA present in said biological sample;

d) determining a ratio value of said amount of PCA3 mRNA over said amount of prostate-specific marker mRNA;

e) comparing said ratio value of said amount of PCA3 mRNA over said amount of prostate specific marker mRNA to at least one predetermined cut-off value,

wherein a ratio value above said predetermined cut-off value is indicative of the presence of a more aggressive cancer as compared to a ratio value below said predetermined cut-off value which is indicative of the presence of a less aggressive cancer.

11. The method of claim 5, wherein the amount of said prostate cancer specific PCA3 mRNA and of said prostate-specific marker mRNA is determined using a hybridization assay.

6. A method for assessing prostate cancer tumor volume in a patient comprising:

a) obtaining a biological sample from said patient;

b) determining the amount of a prostate cancer specific PCA3 nucleic acid and the amount of a prostate-specific marker in said biological sample;

c) determining a ratio value of said amount of said prostate cancer specific PCA3 nucleic acid over said amount of prostate-specific marker; and

d) comparing said ratio value to at least one predetermined cut-off value;

wherein a ratio value above said predetermined cut-off value is indicative of a greater prostate cancer tumor volume as compared to a ratio value below said predetermined cut-off value.

7. A method for monitoring prostate cancer tumor growth in a patient comprising:

a) obtaining biological samples from said patient at a first point in time and a subsequent point in time;

b) determining the amount of a prostate cancer specific PCA3 nucleic acid and the amount of a prostate-specific marker in said biological sample obtained at said first point in time;

c) determining a ratio value of said amount of said prostate cancer specific PCA3 nucleic acid over said amount of prostate-specific marker;

d) repeating b) and c) using said biological sample obtained at said subsequent point in time; and

e) comparing the ratio value obtained in c) with the ratio value obtained in d);

wherein a higher ratio value in d) compared to the ratio value obtained in c) is indicative of the progression of prostate cancer and of a greater tumor volume.

19. The method of claim 7, wherein said biological samples are obtained from a patient undergoing a prostate cancer treatment between said first and said subsequent points in time, thereby monitoring an effect of said treatment on cancer tumor growth or cancer progression.

8. A method for monitoring the progression of prostate cancer in a patient comprising:

a) contacting a biological sample from said patient with at least one oligonucleotide that hybridizes to a prostate cancer specific PCA3 nucleic acid;

b) contacting said biological sample with at least one oligonucleotide that hybridizes to a prostate-specific marker nucleic acid;

c) determining the amount of PCA3 nucleic acid and the amount of prostate-specific marker nucleic acid present in said biological sample;

d) determining a ratio value of said amount of PCA3 nucleic acid over said amount of prostate-specific marker nucleic acid;

e) repeating a) to d) with a biological sample obtained from said patient at a subsequent point in time; and

f) comparing the ratio value obtained in d) with the ratio value obtained in e),

wherein a higher ratio value in e) compared to the ratio value obtained in d) is indicative of the progression of prostate cancer.

15. A method for determining the risk of progression of prostate cancer in a patient after therapy comprising:

a) obtaining biological samples from said patient before and after said therapy;

b) determining the amount of a prostate cancer specific PCA3 nucleic acid and the amount of a prostate-specific marker in said biological sample obtained before said therapy;

c) determining a ratio value of said amount of said prostate cancer specific PCA3 nucleic acid over said amount of said prostate-specific marker;

d) repeating b) and c) using said biological sample obtained after said therapy; and

e) comparing the ratio value obtained after therapy with the ratio value obtained before therapy,

wherein a higher ratio value in said sample after therapy compared to the ratio value obtained before therapy is indicative of the progression of prostate cancer.

18. A method for staging prostate cancer in a patient comprising:

a) obtaining a biological sample from said patient;

b) determining the amount of a prostate cancer specific PCA3 nucleic acid and the amount of a prostate-specific marker in said biological sample;

c) determining a ratio value of said amount of said prostate cancer specific PCA3 nucleic acid over said amount of prostate-specific marker;

d) comparing said ratio value with at least one predetermined cut-off value; and

e) correlating a ratio value with a particular stage of prostate cancer,

wherein a ratio value above a predetermined cut-off value indicates a more advanced stage of prostate cancer as compared to a ratio value below said predetermined cut-off value, thereby staging prostate cancer in said patient.

20. A method for prognosing prostate cancer in a human patient, comprising:

a) performing an in vitro nucleic acid amplification assay on a biological sample from said patient or extract thereof using a first primer pair which is specific to a prostate cancer specific PCA3 nucleic acid sequence and a second primer pair which is specific to a prostate-specific marker nucleic acid sequence;

b) quantifying said PCA3 nucleic acid sequence and said prostate-specific marker nucleic acid sequence; and

c) calculating a normalized ratio of PCA3 over said prostate-specific marker, wherein said ratio can be correlated to a PCA3 mRNA level and a prostate-specific marker mRNA level in said patient,

wherein said normalized ratio of PCA3 over said prostate-specific marker positively correlates with a grade or stage of prostate cancer.